ISRCTN88861431已完成不适用
Study of safety and immunogenicity of Measles vaccine (Rouvax®) administered by transcutaneous route (France)
World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)0 个研究点目标入组 0 人开始时间: 2005年11月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Healthy adults between 18 and 22 years of age of haplotype HLA-A201 who have previously been immunised against measles and for whom the anti-measles antibodies are low
- •2. Female participants must be under contraception
排除标准
- •1. Previous infection with measles
- •2. Contra-indications to the use of Rouvax® vaccine
- •3. Hypersensitivity to egg proteins
- •4. Human Immunodeficiency Virus (HIV) seropositive
- •5. Treatment with corticosteroids or immunosuppressors in 15 days prior to enrolment
- •6. Exposure of back-skin to sun in 15 days prior to enrolment
- •7. Dermatological pathology on back
- •8. Acute and evolutive disease
- •9. Blood donation in three months prior to enrolment
- •10. In a period of exclusion following previous clinical trials
- •11. Having received 3800 or more Euros in preceeding 12 months from participation in clinical trials
研究者
相似试验
进行中（未招募）
1 期
MMR-3 research; The effect of a third vaccination with the mumps, measles and rubella combination vaccine on the immunity against the mumps virus in healthy young adults.immunological response to an extra mumps immunization (in healthy volunteers)EUCTR2016-001104-36-NLRIVM147
已完成
不适用
Third MMR vaccine dose in young adultsMMR vaccinationMumps, Measles and RubellaMumps outbreakImmunogenicity and toleranceAntibody response and cellular immunityBMR vaccinatieBof, Mazelen en Rode HondBof uitbraakImmunogeniciteit en veiligheidAntistof respons en cellulaire immuniteitNL-OMON20600ational Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control (CIb)150
尚未招募
不适用
Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)COVID-19PACTR202004693933092Misr University for Science and Technology200
已完成
不适用
Safety of an aerosol attenuated measles vaccine in healthy subjects with Omron's nebuliser, Aerogen's clinical nebuliser and Trudell's nebuliserISRCTN03256458World Health Organization (WHO) (Switzerland)60
已完成
不适用
Characterization of immune mechanisms in measles and other infectious diseasesNL-OMON22598RIVM419